COVID-19 Lesson: India Earmarks $1.3bn To Reduce Dependence On China
Lopinavir, Ritonavir On List Of 53 Incentivized APIs
Executive Summary
In a bid to ensure long-term medicines security, the Indian government has earmarked $1.32bn to promote domestic production of 53 APIs, including lopinavir and ritonavir currently being evaluated to treat COVID-19 cases, as well as antibiotics, for which India is highly dependent on China.
You may also be interested in...
India’s Interim Budget Pushes Innovation, Green Production, HPV Vaccination
India’s interim budget 2024 hikes allocation for production-linked incentive schemes in pharmaceuticals, supports biotech start-ups - particularly green ones- and sets the right note for inclusion of HPV vaccination in the country’s Universal Immunization Program, one of the world's largest public health programs. How does it help?
AI/ML Efforts, Quick Approvals, Regulator Digitalization: What India Is Doing For Drug Discovery
AI initiatives in a country known for its software prowess, along with startup support, clinical trial rule changes, crunched approval timelines, unified digital regulatory interfaces and a R&D policy laying out $600m in funds, are all meant to build something greater than the sum of its parts. In a bottom-up approach, India is building an innovation ecosystem
What To Expect From India’s Proposed National Pharmaceutical Policy
An updated National Pharmaceutical Policy aimed at enhancing India’s self-reliance and global competitiveness is on the cards. A focus on private-public partnering and academia-industry linkages means much of its success will depend on the ability of various parties to deliver within the constraints they operate in